Investment

Cell & Gene Therapy

Cell therapy's second act: why Boston is still winning

Four years after the first wave of CAR-T IPOs, Massachusetts is quietly becoming the centre of gravity for the next generation of cell therapies — this time, for solid tumours.

When the FDA approved the first CAR-T therapy for leukaemia in 2017, the assumption across the industry was that the blood cancer playbook would translate quickly into solid tumours. It did not.

Mark Walker  · 
AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Diagnostics
Digital Health

Gates Foundation and Wellcome Leap commit $100m to cut stillbirths

The Uzima programme targets a 50% reduction in stillbirth rates across select countries over a decade, led by AI diagnostics and biomarker tools.
The Uzima programme targets a 50% reduction in stillbirth rates across select countries over a decade, led by AI diagnostics and biomarker tools.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

XORTX plans Health Canada CTA filing for gout candidate XRx-026

The Calgary biotech aims to file a Clinical Trial Application in Canada to accelerate data generation for its planned FDA NDA submission for XORLO.
The Calgary biotech aims to file a Clinical Trial Application in Canada to accelerate data generation for its planned FDA NDA submission for XORLO.
The Biotech Times Editorial Team  · 
Medical Devices
Pharmaceuticals

Beyond Air posts record $2.3m quarter as LungFit PH adoption grows

Beyond Air said Q3 2026 revenue rose 30% sequentially to $2.3m, its highest ever, while its second-generation nitric oxide system awaits FDA approval.
Beyond Air said Q3 2026 revenue rose 30% sequentially to $2.3m, its highest ever, while its second-generation nitric oxide system awaits FDA approval.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biotech

Tilray Brands posts record Q1 revenue of $257m, up 23% year-on-year

Tilray Brands reported record first-quarter net revenue of $257m, driven by beverage growth and EMEA expansion, while reaffirming its fiscal 2027 adjusted EBITDA
Tilray Brands reported record first-quarter net revenue of $257m, driven by beverage growth and EMEA expansion, while reaffirming its fiscal 2027 adjusted EBITDA
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Pacira grants Molteni exclusive EXPAREL rights across EU and UK

Pacira BioSciences has licensed its liposomal bupivacaine analgesic to Italian firm Molteni Farmaceutici, targeting first commercial sales in Europe by 2027.
Pacira BioSciences has licensed its liposomal bupivacaine analgesic to Italian firm Molteni Farmaceutici, targeting first commercial sales in Europe by 2027.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics

NeuroOne joins Dartmouth NIH grant for neurotransmitter sensing

NeuroOne will receive around $200,000 from a $1 million NIH BRAIN Initiative grant to co-develop real-time neurotransmitter sensing with Dartmouth College.
NeuroOne will receive around $200,000 from a $1 million NIH BRAIN Initiative grant to co-develop real-time neurotransmitter sensing with Dartmouth College.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Retension Pharmaceuticals raises $45m in Nasdaq IPO for RTN-001

The Virginia-based cardiovascular biotech priced 3.75 million shares at $12 each to fund its Phase 2b and planned Phase 3 trials of RTN
The Virginia-based cardiovascular biotech priced 3.75 million shares at $12 each to fund its Phase 2b and planned Phase 3 trials of RTN
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health
Biotech

Al Ghurair launches Trellis Health hospital network in Dubai

The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

X4 Pharmaceuticals secures $150m debt facility with K2 HealthVentures

The Boston rare-haematology biotech refinanced its existing loan and gains fresh capital to support mavorixafor's Phase 3 trial and potential commercial launch.
The Boston rare-haematology biotech refinanced its existing loan and gains fresh capital to support mavorixafor's Phase 3 trial and potential commercial launch.
The Biotech Times Editorial Team  · 
Medical Devices

MMI raises $125m Series D to scale Symani robotic microsurgery

Medical Microinstruments secured the oversubscribed round to expand its Symani Surgical System globally, with around 50 systems installed and 3,500 procedures completed.
Medical Microinstruments secured the oversubscribed round to expand its Symani Surgical System globally, with around 50 systems installed and 3,500 procedures completed.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Genomics
Bioprocessing

UAE biopharma push targets double-digit precision medicine growth

A Frost & Sullivan report for World Health Expo projects over 10% annual precision medicine growth in the Middle East over the next five to seven
A Frost & Sullivan report for World Health Expo projects over 10% annual precision medicine growth in the Middle East over the next five to seven
The Biotech Times Editorial Team  · 
Biotech
Bioinformatics

Bexorg wins up to $28.3m ARPA-H award to extend human brain perfusion

The New Haven CNS platform company will use the 36-month grant to push its BrainEx system from 24-hour to two-week intact human
The New Haven CNS platform company will use the 36-month grant to push its BrainEx system from 24-hour to two-week intact human
The Biotech Times Editorial Team  · 
Medical Devices
Pharmaceuticals
Regulatory Science

Kaléo wins $96m BARDA contract for 2-PAM nerve agent auto-injector

The Virginia biotech secured a Project BioShield award to advance its pralidoxime auto-injector through FDA approval and initial stockpile procurement.
The Virginia biotech secured a Project BioShield award to advance its pralidoxime auto-injector through FDA approval and initial stockpile procurement.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Vaxcyte raises ~$1bn via equity and convertible notes to fund VAX-31

Vaxcyte priced concurrent equity and $500m convertible note offerings to bankroll its 31-valent pneumococcal vaccine through Phase 3 and potential US launch.
Vaxcyte priced concurrent equity and $500m convertible note offerings to bankroll its 31-valent pneumococcal vaccine through Phase 3 and potential US launch.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Gate Bioscience expands Lilly deal to target hard-to-drug proteins

The Brisbane biotech adds at least one new target to its Lilly collaboration, with total milestone-contingent deal value potentially exceeding $870 million.
The Brisbane biotech adds at least one new target to its Lilly collaboration, with total milestone-contingent deal value potentially exceeding $870 million.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Jupiter Neurosciences doses first patient in Phase 2a Parkinson's trial

Jupiter Neurosciences has begun dosing in the RESET trial of JOTROL in Parkinson's disease while simultaneously exploring a sale or licensing of its assets.
Jupiter Neurosciences has begun dosing in the RESET trial of JOTROL in Parkinson's disease while simultaneously exploring a sale or licensing of its assets.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

RougeTx launches with $58m Series A to target HHT bleeding disorder

The Leiden spin-out is advancing RTX-001, a once-daily oral pericyte-targeting candidate, toward first-in-human trials in a condition with no
The Leiden spin-out is advancing RTX-001, a once-daily oral pericyte-targeting candidate, toward first-in-human trials in a condition with no
The Biotech Times Editorial Team  · 
Subscribe to Investment